Medical device company moves from Kendall Square to Medford

Seventh Sense Biosystems (7SBio) is relocating from Cambridge’s Kendall Square to Cummings Properties’ 200 Boston Avenue building in Medford. The firm, which develops blood collection and diagnostic platforms, has grown steadily, moving three times since its founding in 2008.

Cummings Properties leasing manager Derek Cook worked with Mark Winters of Cushman & Wakefield to find the ideal space for 7SBio. The privately held medical technology company will move this month into its new 9,000-square-foot suite, which is a combination of clean room, lab, and office space.

“It’s not at all unusual for businesses to migrate outside the city as they grow,” according to Cook. “The labs throughout our suburban portfolio provide a value that allows firms to save significantly on rent and dedicate more resources to research and development.”

7SBio is the fourth growing company to leave Cambridge for one of Cummings’ suburban locations during the past year. Its move follows relocations by Blue Stream Laboratories, CONTINUUS Pharmaceuticals, and Peritia.

“We were pleased to be able to satisfy Seventh Sense Biosystems’ immediate need for a clean room for manufacturing—something that is essential to its processes,” said Cook. “We also have the capacity in our 10 million-square-foot portfolio to allow the company to expand in the future.”

7SBio is best known for its proprietary Touch Activated Phlebotomy (TAP™) “The facility at 200 Boston is the right combination of quality laboratory and manufacturing space, value, and access to the entire metro area that we were looking for as we begin to commercialize our first products in 2016,” said Weisman.

The company announced in August that it has been granted a total of seven (7) patents in the U.S. and Europe with many more under review around the world.

Situated just north of Cambridge Cummings Properties’ 196/200 Boston Avenue campus is home to more than 20 businesses, including a dozen life sciences firms and Tufts University’s Bio-cluster Lab.

About the TAP Touch Activated Phlebotomy® and TAP Blood Collection Device®

TAP is a proprietary platform that draws capillary blood in a painless, one-step process without having to access a vein, and it can be utilized across and integrated with a broad spectrum of diagnostic applications. The TAP system penetrates the uppermost layers of skin through the use of micro-needles, collects capillary blood using a novel microfluidic extraction process, and stabilizes the blood with anticoagulant if required. The device has a visual indicator to confirm that collection is complete. The TAP platform is designed for fully automated, high throughput manufacturing.

About Seventh Sense Biosystems, Inc.

Founded in 2008, within Flagship VentureLabs™, 7SBio is developing and commercializing an array of products based on the company’s proprietary Touch Activated Phlebotomy (TAP™) painless blood collection platform, with an initial focus on enabling important diagnostic testing at the point of care by reducing the discomfort, anxiety and hassle of blood sample collection that can inhibit and sometimes prevent patients from undergoing blood tests and receiving appropriate care. Please also refer to our website at www.7sbio.com